Mark A. Velleca, M.D., Ph.D.

Mark A. Velleca, M.D., Ph.D.

President and Chief Executive OfficeratBlack Diamond Therapeutics· In proxies 2023–2025

Pay in FY2025-22% from the year before · Black Diamond Therapeutics stock +13.6% the same year

Mark A. Velleca, M.D., Ph.D. was paid $2.2M in FY2025 (Dec), down 22%. Black Diamond Therapeutics stock rose 13.6% that year.

Pay$100 in the stock at the end of FY23 → $86
Pay is from the Summary Compensation Table of each Black Diamond Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Black Diamond TherapeuticsPublic company · 3 yr
    • President and Chief Executive Officer2023 – Present · 3 yrStock in role +43%
  2. Myeloid Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. iOncturaPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?